Selective detection of bone metastases in renal clear cell carcinoma
EP2219668A1
Binding epitopes for g250 antibody
US2008138275A1
Hybridoma cell line G250 and its use for producing monoclonal antibodies
AU2006230697A1
Hybridoma cell line G250 and its use for producing monoclonal antibodies
WO2007025718A1
Oxadiazole compounds as urokinase inhibitors
KR20080027875A
Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
US2009202550A1
Monoclonal antibodies specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
US2008039626A1
Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds
BRPI0512854A
improved adjuvant therapy for g250 expressing tumors
DE102004057195A1
Crystalline modifications of N-alpha (2,4,6-triisopropylphenylsulfonyl) -3-hydroxyamidino- (L) -phenylalanine-4-ethoxycarbonylpiperazide and / or salts thereof
DE102004045720A1
Stable dosage form of phenylalanine derivatives
US2004138233A1
Urokinase inhibitors and uses thereof
AU2003231596A1
Diagnostic and therapeutic use of antibodies against the urokinase receptor
AU2003253326A1
Method for the production of phenylalanine derivatives
WO2004002526A1
Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
DE10323898A1
Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
DE10259844A1
New mannopyranoside-based peptidomimetic compounds, useful for treatment or diagnosis of e.g. intestinal, autoimmune or tumor diseases, are selective alpha4, beta7-integrin antagonists
AU2002352245A1
Selective arylguanidine peptides as urokinase inhibitors
DE10240452A1
New (hetero)aryl-guanidine or -amidine compounds, are potent and selective urokinase-plasminogen activator inhibitors, useful for treating tumors or metastasis formation
